1. Introduction {#sec1-diseases-03-00193}
===============

Cancer is a leading cause of human death in the United States \[[@B1-diseases-03-00193]\]. The clinical management of cancer invariably involves diverse conventional modalities, including surgery, radiation, and chemotherapy \[[@B1-diseases-03-00193],[@B2-diseases-03-00193]\]. Because commonly used chemotherapeutic agents usually affect processes that occur in all rapidly dividing cells, many normal cells throughout the body that are undergoing active growth and cell division can also be damaged. As a result, chemotherapeutic agents induce significant side effects \[[@B3-diseases-03-00193]\]. To reduce the adverse effects caused by chemotherapeutic agents, in recent years, targeted therapies were developed to interact with specific molecules that are part of the pathways \[[@B4-diseases-03-00193]\].

Tumor growth and progression depend on angiogenesis, a process of new blood vessel formation from a preexisting vascular endothelium. The newly formed blood vessels provide nutrients and oxygen to the tumor, increasing its growth. Inhibiting angiogenesis has been proposed as a potential cancer treatment strategy \[[@B5-diseases-03-00193]\]. Therefore, angiogenesis is considered as a powerful target to suppress tumor growth and metastasis \[[@B6-diseases-03-00193],[@B7-diseases-03-00193]\].

Complementary and alternative medicine (CAM), which covers a wide spectrum of ancient to new-age approaches that purport to expand options for preventing and treating diseases, is gaining more attention for cancer management \[[@B8-diseases-03-00193],[@B9-diseases-03-00193],[@B10-diseases-03-00193]\]. The emergence of CAM represents a natural experiment of huge dimensions, as millions of Americans have begun self-medicating with natural products \[[@B11-diseases-03-00193],[@B12-diseases-03-00193]\]. Natural products have been valuable sources of new therapeutic candidate compounds \[[@B13-diseases-03-00193],[@B14-diseases-03-00193],[@B15-diseases-03-00193]\]; an analysis of the number of chemotherapeutic agents and their sources indicates that nearly 80% of approved drugs are derived from natural compounds \[[@B16-diseases-03-00193]\]. With the advent of high throughput screening technologies, natural products are likely to provide many of the lead structures for the construction of novel compounds with enhanced anticancer properties.

Natural products are most often administered orally so that they are exposed to the trillions of microbial organisms that live in the gut. Previous reports revealed that compound biotransformation resulted from reactions carried out by the enteric microbiome \[[@B17-diseases-03-00193]\]. These studies involved monitoring compound metabolism during the *ex vivo* fecal incubation with a given compound \[[@B18-diseases-03-00193]\], showing that orally ingested natural products can be biotransformed to their metabolites by microbiota in the gut. However, information regarding the role of the enteric microbiome in botanical bioactivity is still limited and this situation obstructs the evaluation of natural products with anticancer potential.

Because ginseng is a very commonly used antioxidant natural product in the U.S, in this review, using American ginseng as an example, we have summarized recent research progress on the anticancer activities of ginseng parent compounds and their intestinal microbiome metabolites, focusing on their angiogenesis inhibitory potentials. Crucial information on ginseng's interactions with the enteric microbiome was obtained and the contribution of intestinal microbiota to ginseng's anticancer activity is discussed. Molecular mechanisms involved in the ginseng metabolites' actions, including those targeted on angiogenesis are discussed.

2. American Ginseng is a Commonly Used Antioxidant Botanical {#sec2-diseases-03-00193}
============================================================

Ginseng is the name of a group of botanicals in the genus *Panax* of the Araliaceae family. Three species in the genus are commonly used as herbal remedies in oriental countries, *i.e.*, Asian ginseng (*Panax ginseng*), notoginseng (*Panax notoginseng*), and American ginseng (*Panax quinquefolius*).

Asian ginseng is distributed in Eastern Asia, including northeastern China, Korea, and the far east of Russia, while commercially available Asian ginseng is cultivated in China and Korea \[[@B19-diseases-03-00193],[@B20-diseases-03-00193]\]. Like Asian ginseng, notoginseng is a Chinese herbal medicine that has a long history of use in Asian countries. Notoginseng is distributed in southwestern China, Burma, and Nepal, and this herb is cultivated commercially in southwestern China \[[@B21-diseases-03-00193],[@B22-diseases-03-00193]\]. The root is the most commonly used plant part of Asian ginseng and notoginseng.

American ginseng is an obligate shade perennial plant native to eastern North America. The commonly used part of the plant is the root, which is harvested after several years of cultivation. Although both the U.S. and Canada have cultivated American ginseng, the largest growing area is in Wisconsin, USA \[[@B23-diseases-03-00193],[@B24-diseases-03-00193]\]. In recent years, American ginseng has also been grown in northeastern China on a small scale, however, studies on the chemical profiles and pharmacological effects of Chinese produced American ginseng are limited \[[@B25-diseases-03-00193]\].

It is generally believed that the active compounds in Asian ginseng, notoginseng and American ginseng are triterpene glycosides or dammarane saponins, commonly referred to as ginseng saponins (ginsenosides and notoginsenosides). These ginseng saponins are the major active ingredients in the herb, and their levels can be used to develop quality controls for these herbs \[[@B26-diseases-03-00193],[@B27-diseases-03-00193],[@B28-diseases-03-00193]\]. There are over 50 different known ginseng saponins, and they are characterized by a four trans-ring rigid steroid aglycone skeleton and attached sugar moieties \[[@B29-diseases-03-00193]\]. Based on the aglycone skeleton, ginseng saponins can be divided into the protopanaxadiol group and protopanaxatriol group, except for ginsenoside Ro, which is derived from the oleanolic acid group ([Figure 1](#diseases-03-00193-f001){ref-type="fig"}).

Although all three ginseng plants have both protopanaxadiol group (PPD group) and protopanaxatriol group (PPT group) saponins, their constituent compositions vary. As we know, ginsenosides Rb1, Rb2, and Rd belong to the PPD group, while ginsenosides Re, Rg1, and notoginsenoside R1 belong to the PPT group. The major saponins in Asian ginseng are ginsenosides Rb1, Rb2, and Rg1; those in notoginseng are ginsenosides Rb1, Rd, Rg1 and notoginsenoside R1; and the major saponins in American ginseng are ginsenosides Rb1, Rd, and Re.

American ginseng has a high saponin content, specifically having abundant PPD group saponins \[[@B30-diseases-03-00193]\]. Previous observations suggested that the PPD group ginsenosides, especially those with lesser sugar moieties, showed more potent anticancer activity \[[@B31-diseases-03-00193],[@B32-diseases-03-00193]\]. The higher PPD group saponin content in American ginseng supplied sufficient resources for further chemical or biochemical transformation to produce active anticancer ginsenosides, which will be discussed later.

Several beneficial effects of American ginseng, such as cardioprotection and adjuvant cancer therapy, have been reported \[[@B33-diseases-03-00193],[@B34-diseases-03-00193]\]. These pharmacologic activities are, to a significant extent, considered to be due to the antioxidant properties of this botanical. Our group observed anti-diabetic and anti-obesity activities of American ginseng extract \[[@B35-diseases-03-00193],[@B36-diseases-03-00193],[@B37-diseases-03-00193]\]. These effects are likely related to the anti-oxidant property of the ginseng compounds. In a clinical trial, ginseng extract prevented acute oxidant injury following cardiac reperfusion \[[@B38-diseases-03-00193]\]. Our group has demonstrated that acute oxidant stress induced cardiomyocyte injury was protected by the treatment of American ginseng \[[@B39-diseases-03-00193]\]. For cancer chemotherapy studies, we observed that American ginseng possesses the potential for treating chemotherapeutic agent-induced side effects, which is partly mediated by antioxidant mechanisms \[[@B40-diseases-03-00193],[@B41-diseases-03-00193]\].

![Chemical structures of ginseng saponins in American ginseng. Rg3, F2, and CK are gut microbiome metabolites of PPD group saponins.](diseases-03-00193-g001){#diseases-03-00193-f001}

3. Biotransformation of American Ginseng Saponins {#sec3-diseases-03-00193}
=================================================

Bacteria are an important component of the human body. The microbiome is a community of living microorganisms assembled in particular ecological niches of a host that contain trillions of bacterial cells, 10 times more cells than the number of cells constituting the body \[[@B42-diseases-03-00193]\]. A considerable portion (approximately 70%) of this microbial cosmos is localized in the gut, while the colon is the site where the gut microbiota reaches its highest concentration \[[@B43-diseases-03-00193]\].

Like many other herbal medicines, the route of administration of American ginseng is nearly always oral. After oral ingestion, ginseng saponins are metabolized extensively by intestinal microbiota. Although investigations on the comprehensive metabolic profile of American ginseng are very limited because of the chemical complexity and limitation of analytical methods, we recently systemically evaluated the biotransformation and metabolic profiles of American ginseng extract by human intestinal microflora. Using a highly sensitive and selective liquid chromatography/quadrupole time-of-flight mass spectrometry method, 25 metabolites were detected, of which 15 metabolites were derived from original protopanaxadiol saponins, including the three highest ones. This indicated that the PPD-type ginsenosides generated comprehensive biotransformation and were more easily metabolized than other ginsenosides under the same conditions. Several major metabolic pathways can be observed for PPD-type ginseng saponins by human intestinal microbiota such as deglycosylation and dehydration. One way is to selectively eliminate the *C*-3 sugar moieties to produce F~2~ and then compound K (CK) \[[@B44-diseases-03-00193],[@B45-diseases-03-00193]\]. CK can be further converted to 3-oxo-compound K and monooxygenated compound K. Another way is to selectively eliminate the *C*-20 sugar chain to produce ginsenoside Rg~3~ \[[@B46-diseases-03-00193]\]. It is interesting to note that Rg~3~ can be further transformed to Rk~1~ and Rg~5~ by intestinal microflora via dehydration ([Figure 2](#diseases-03-00193-f002){ref-type="fig"}) \[[@B46-diseases-03-00193]\].

![Metabolic pathways of PPD group ginseng saponins converted by the intestinal microbiome.](diseases-03-00193-g002){#diseases-03-00193-f002}

The three most abundant metabolites are ginsenoside Rg~3~, ginsenoside F~2~, and CK, which are transformed from ginsenosides Rb1, Rb2, Rb3, Rc, and Rd ([Figure 1](#diseases-03-00193-f001){ref-type="fig"}). The main metabolic pathways of ginseng saponins are deglycosylation reactions by intestinal microflora through the stepwise cleavage of sugar moieties. Subsequent dehydration reactions also occur. Compared to those of the PPT group, PPD group triterpenoids are easy to metabolize.

We recently observed that CK showed significant antiproliferative effects on human colorectal cancer cells, while its parent compound Rb1 did not show any effects at the same concentrations \[[@B47-diseases-03-00193]\]. Thus, ginseng's bioactivity appears to be highly dependent on metabolism by enteric microbiota. Several microbial species including *Prevotelki oris* appear to have this capability \[[@B44-diseases-03-00193],[@B45-diseases-03-00193],[@B48-diseases-03-00193]\]. However, information on the role of enteric microbiota in ginseng's cancer chemoprevention is still not clear. Nevertheless, available evidence has suggested that the intestinal microbiota may play an important role in mediating the metabolism and bioactivity of American ginseng.

4. Effects of Ginsenoside Metabolites on Cancer Cell Death Induction {#sec4-diseases-03-00193}
====================================================================

Early ginseng anticancer evaluations largely focused on the herb's parent compounds, *i.e.*, the ginsenosides Rb1, Rd, and Re. The antiproliferative effects of these ginsenosides on different cancer cell lines were evaluated. Unfortunately, in several *in vitro* screenings, even in very high concentrations, these parent compounds did not show obvious antiproliferative activities \[[@B31-diseases-03-00193],[@B49-diseases-03-00193]\].

Orally administered ginsenosides are poorly absorbed, and some appear to require bacterial metabolism to be absorbed and biologically active \[[@B50-diseases-03-00193]\]. After ginseng ingestion, both Rg3 and CK are major metabolites reaching the systemic circulation \[[@B29-diseases-03-00193],[@B46-diseases-03-00193],[@B51-diseases-03-00193]\]. CK possesses very significant anticancer activities compared to its parent compound Rb1 \[[@B52-diseases-03-00193]\]. The IC~50~ of CK for the inhibition of colon cancer cell proliferation was 30--50 µM, suggesting that its antiproliferative effect is greater than that of Rg3 (IC~50~ 100--150 µM), the compound derived from Rb1 via steaming treatment \[[@B47-diseases-03-00193],[@B53-diseases-03-00193],[@B54-diseases-03-00193]\].

Although ginsenoside Rg3 showed moderate antiproliferative effects, Rg3 was approved as a new anti-cancer drug in China \[[@B55-diseases-03-00193]\]. Rg3 has been shown to inhibit NF-κB signaling \[[@B56-diseases-03-00193]\] and enhances the susceptibility of prostate cancer cells to docetaxel and other chemotherapeutics \[[@B57-diseases-03-00193]\]. We observed that the inhibitory effect of Rg3 on colon cancer cells is in part mediated by inhibiting β-catenin/Tcf transcriptional activity and suppressing PNCA expression in colon tumors, thus inducing cancer cell apoptosis \[[@B58-diseases-03-00193]\].

CK induced apoptosis in several tumor cell lines by regulating various signaling pathways, such as the activation of caspase-8 \[[@B59-diseases-03-00193]\] and AMP-activated protein kinase (AMPK) \[[@B60-diseases-03-00193],[@B61-diseases-03-00193]\], suppression of nuclear factor-kappa B (NF-кB) pathways \[[@B62-diseases-03-00193]\] and Janus activated kinase 1 (JAK1)-signal transducer and activator of transcription 3 (STAT3) signaling \[[@B63-diseases-03-00193]\]. A recent study indicated that CK increased generation of reactive oxygen species and activation of c-Jun NH2-terminal kinase signaling pathway, which in turn stimulated autophagy and apoptosis in human colon cancer cells \[[@B64-diseases-03-00193]\]. Our data showed that multiple pathways, including p53/p21, PI3K/Akt, and transforming growth factor beta (TGF-β), were involved in CK induced cancer cell death \[[@B65-diseases-03-00193]\].

5. The Role of Ginsenoside Metabolites in Angiogenesis for Cancer Treatment {#sec5-diseases-03-00193}
===========================================================================

Anti-angiogenic compounds have emerged as potential agents to be used alone or in combination with other chemotherapeutic drugs for the treatment of cancer. Early studies have revealed that red ginseng extract inhibited tumor metastasis, and active compound ginsenoside Rg3 exhibited a significant decrease in the number of blood vessels oriented toward the tumor mass \[[@B66-diseases-03-00193]\]. As shown in [Figure 2](#diseases-03-00193-f002){ref-type="fig"}, Rg3 is also a major intestinal metabolite from parent PPD group ginsenosides. Rg3 was found to inhibit the proliferation of human umbilical vein endothelial cells.

The vascular endothelial growth factor (VEGF) is an important growth factor that promotes angiogenesis. Overexpression of VEGF results in increased angiogenesis, whereas its suppression results in the inhibition of angiogenesis in both normal and pathological conditions. Increased VEGF expression is associated with solid tumor growth, and its inhibition has been shown to be effective in the control of several cancers \[[@B67-diseases-03-00193]\]. Rg3 suppressed the capillary tube formation of the cells in the presence or absence of VEGF. The VEGF-induced cell chemoinvasions were significantly attenuated by Rg3 \[[@B68-diseases-03-00193]\].

Rg3 also showed anti-angiogenic effects on pulmonary, gastric, and ovarian cancers \[[@B69-diseases-03-00193],[@B70-diseases-03-00193],[@B71-diseases-03-00193]\]. As a potential angiogenic inhibitor, Rg3 processed synergistic effects when it was used in combination with other cancer chemotherapeutic agents, such as gemcitabine, cyclophosphamide, and capecitabine \[[@B72-diseases-03-00193],[@B73-diseases-03-00193],[@B74-diseases-03-00193]\]. The combination use of chemotherapeutic agent plus angiogenesis inhibitor could be a promising strategy in cancer management.

As a major ginsenoside metabolite in the gut, CK showed significant anticancer activity. In early studies, in addition to inducing cancer cell apoptosis, CK also showed antiplatelet and anti-angiogenic activities and caused the suppression of primary tumor growth in a spontaneous metastasis model \[[@B45-diseases-03-00193]\]. MMPs (matrix metalloproteinases), especially MMP-9, involved in extracellular matrix degradation, are crucial for the endothelial cell migration, organization, and angiogenesis \[[@B75-diseases-03-00193]\]. It has been reported that MMP-9 expression levels are significantly higher in tumors than in normal tissue. The upregulation of MMP-9 is implicated in the process of invasion and metastasis of malignancies \[[@B76-diseases-03-00193]\]. CK significantly inhibited the secretion and protein expression of MMP-9. The inhibitory effect of compound K on MMP-9 expression was correlated with decreased MMP-9 mRNA levels and the suppression of MMP-9 promoter activity \[[@B77-diseases-03-00193]\].

Using human umbilical vein endothelial cells (HUVECs), the molecular mechanisms of the anti-angiogenic effects of CK were further evaluated. CK significantly inhibited the migration and tube formation of HUVECs at non-cytotoxic concentrations, reduced the secreted level of VEGF and increased the secreted level of pigment epithelium-derived factor (PEDF) in HUVECs. The anti-angiogenic activity of CK was found to be a result of the inhibition of p38 MAPK and AKT in the HUVECs \[[@B78-diseases-03-00193]\]. Anti-angiogenic effects of CK were also validated by a recently published study \[[@B79-diseases-03-00193]\]. Therefore, the anti-angiogenic effects of CK might have therapeutic potential for controlling the growth and invasiveness of different cancers.

6. Conclusions {#sec6-diseases-03-00193}
==============

Anti-angiogenic compounds have emerged as potential agents to be evaluated for the treatment of cancer. Many anticancer agents have been developed from botanical sources. American ginseng is a commonly used antioxidant herbal medicine in the United States. Ginsenoside Rg3 and CK are major ginseng metabolites biotransformed by the enteric microbiome. Compared to their parent compounds, these metabolites exert much better anticancer activities with multiple molecular mechanisms. Interestingly, both Rg3 and CK also showed significant anti-angiogenic effects on pulmonary, gastric, and ovarian cancers. Therefore, in addition to the chemopreventive effects of ginseng compounds, as angiogenic inhibitors, ginsenoside metabolites could be used in combination with other cancer chemotherapeutic agents in cancer management.
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